Dapsone hypersensitivity syndrome  

作　　者：Qing Zhao Lele Sun Yonghu Sun Dean Naisbitt Hong Liu Furen Zhang 

机构地区：[1]Shandong Provincial Hospital for Skin Diseases&Shandong Provincial Institute of Dermatology and Venereology,Shandong First Medical University&Shandong Academy of Medical Sciences,Jinan,Shandong 250022,China [2]Department of Molecular and Clinical Pharmacology,MRC Centre for Drug Safety Science,University of Liverpool,Liverpool,UK

出　　处：《Chinese Medical Journal》2023年第13期1560-1562,共3页中华医学杂志（英文版）

基　　金：Academic promotion program of Shandong First Medical University(Nos.2019LJ002,2019RC007,2020RC001);Youth technology Innovation Support Project of Shandong Colleges and Universities(No.2019KJL003);National Natural Science Foundation of China(Nos.81811530342,81972946,81903224,82103734);Shandong Provincial Foreign Expert Project(No.WST2019004);China Scholarship Council(No.201806220227)

摘　　要：Dapsone hypersensitivity syndrome(DHS)was first reported by Lowe and Smith[1]in 1949 in Nigeria and was termed“dapsone syndrome”by Allday and Barnes[2]in 1951.DHS is a drug-induced hypersensitivity syndrome(DIHS)caused by dapsone 404’-diaminodiphenylsulfone(DDS).DHS is characterized by fever,rash,lymphadenopathy,and hepatitis,which usually develop after patients receive DDS for 5 to 6 weeks.Epidemiological studies have estimated DHS prevalence and fatality rates of 1.4%and 9.9%,respectively.[3]Until recently,the“wait and see”approach was used for patients with suspected DHS.Herein,we review recent developments in DHS research,focusing on its etiology,pathogenesis,diagnosis,and prevention,to make DDS a safer medication for most of the population through the prospective exclusion of susceptible patients before DDS administration.

关 键 词：DHS PREVENTION DIAGNOSIS 

分 类 号：R969[医药卫生—药理学]